Replies to post #199430 on Biotech Values

[DewDiligence]

ENTA -8% on no news. Evidently, investors are literally interpreting Rick Gonzalez’s guidance for 2016 V-Pak sales of $2B—even though Gonzalez himself acknowledged on ABBV’s 4Q15 CC that $2B is a lowball figure ABBV is using to ensure a “beat” (after the embarrassment of missing the V-Pak end-2015-run-rate guidance).

[DewDiligence]

ABBV/ENTA—Viekira Pak’s* EU label now allows excluding ribavirin for GT1b patients with mild (Child-Pugh A) cirrhosis:

http://finance.yahoo.com/news/abbvie-receives-chmp-positive-opinion-143300715.html

This recommendation by the CHMP will be rubber-stamped by the EU Commission in 2-3 months.

*Viekira Pak brand name in EU is “Viekirax + Exviera”.